Rapid pain control in Ixekizumab targeted axial spondyloarthritis

You may not qualify if:

• prior exposure to bDMARDs
• previous Ixekizumab treatment within 4 weeks (or 5 half-lives, whichever is longer) prior to enrolment
• any contraindication to perform MRI
• any severe active infection, e.g. hepatitis B or C, SARS-CoV 2 (COVID 19), or active tuberculosis as defined by a positive Quantiferon Tb-test. (if presence of latent tuberculosis is established then treatment according to local guidelines must have been initiated prior to enrolment) or history of recurrent infections
• any other autoimmune or inflammatory disease (e.g. but not limited to RA, SLE, SSc, MCTD, Behcet disease, vasculitis, or autoimmune hepatitis)
• presence of fibromyalgia or other forms of widespread pain at the discretion of the investigator
• requirement for immunization with live vaccine during trial participation or within the four weeks prior to screening
• history of venous thrombosis or pulmonary embolism
• any condition, including the presence of laboratory abnormalities, which would impact the safety of the subject or the interpretation of the trial results
• history of or presence of inflammatory bowel disease including Crohn’s disease and ulcerative colitis
• Clinically significant cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, neurologic, gastrointestinal, immunologic, or other major diseases
• Evidence of severe renal dysfunction defined as: eGFR < 30 ml/min/1,73 m2 (calculated using the MDRD formula) at screening (Visit 1)
• Evidence of severe hepatic insufficiency defined as Child-Pugh score ≥ 10 (C)
• treatment with Glucocorticoids of more than 10 mg/day